New clinical reports demonstrate that targeting the biological pathways of hormone and peptide growth factor receptors holds promise for the prevention and treatment of breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wickerham, D.L. et al. The initial results from NSABP protocol P-1: A clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Proc. Amer. Soc. Clin. Oncol. 17, 2a (Abstract #3a) (1998).
Cummings, S.R. et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluations (MORE) trial. Proc. Amer. Soc. Clin. Oncol. 17, 2a (abstract # 3) (1998).
Jordan, V.C. et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ∼12,000 postmenopausal women. Proc. Amer. Soc. CHn. Oncol. 17, 122a (Abstract #466) (1998).
Cobleigh, M.A. et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Amer. Soc. din. Oncol. 17, 97a (Abstract #376) (1998).
Slamon, D. et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER27MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial. Proc. Amer. Soc. Clin. Oncol. 17, 98a (Abstract # 377) (1998).
Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. The Lancet 351, 1451–1467 (1998).
Grese, T.A. et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA 94, 14105–14110 (1997).
Delmas, P.D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641–1647 (1997).
Reese, D.M. & Slamon, D. HER-2/NEU signal transduction in human breast and ovarian cancer. Stem Cells 15, 1–8 (1997).
Newby, J.C., Johnston, S.R.D., Smith, I.E. & Dowset, M. Expression of epidermal growth factor receptor and c-ErbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 3, 1643–1651 (1997).
Pietras, R.J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435–2446 (1995).
Disis, M.L., Crabstein, K.H., Sleath, P.R. & Cheever, M.A. HER-2/Neu peptide vaccines elicit T cell immunity to the HER-2/Neu protein in patients with breast and ovarian cancer. Proc. Amer. Soc. Clin. Oncol. 17, 97a (Abstract #375) (1998).
Singh, J. et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the ErbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130–1135 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nass, S., Hahm, H. & Davidson, N. Breast cancer biology blossoms in the clinic. Nat Med 4, 761–762 (1998). https://doi.org/10.1038/nm0798-761
Issue Date:
DOI: https://doi.org/10.1038/nm0798-761
This article is cited by
-
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
Oncogene (2000)
-
Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation
Oncogene (1999)
